Key result
Targeting the lymphatic route for drug delivery in cardiovascular medicine is an emerging strategy to avoid the hepatic first-pass effect and optimize the efficacy of new generation treatments.
Why the study?
New cardiovascular therapies are exploring alternative administration options to reduce dosing frequency, improve efficacy, and avoid hepatic first-pass metabolism by targeting the lymphatic route.
Targeting the lymphatic route for drug delivery offers a promising alternative to oral administration in cardiovascular medicine by avoiding the hepatic first-pass effect.
Lymphatic targeting merits exploration for CV drugs; leaves open clinical translation pending prospective trials.
While oral agents have been the gold standard for cardiovascular disease therapy, the new generation of treatments is switching to other administration options that offer reduced dosing frequency and more efficacy. The lymphatic network is a unidirectional and low-pressure vascular system that is responsible for the absorption of interstitial fluids, molecules, and cells from the peripheral tissue, including the skin and the intestines. Targeting the lymphatic route for drug delivery employing traditional or new technologies and drug formulations is exponentially gaining attention in the quest to avoid the hepatic first-pass effect. The present review will give an overview of the current knowledge on the involvement of the lymphatic vessels in drug delivery in the context of cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Tessier et al. (2021) conducted a review in Cardiovascular disease. Lymphatic route drug delivery was evaluated. Targeting the lymphatic route for drug delivery in cardiovascular medicine is an emerging strategy to avoid the hepatic first-pass effect and optimize the efficacy of new generation treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: